December 27, 2004.
The food and drug administration on Friday approved a new drug designed to treat the leading cause of blindness in older Americans. Age-related macular degeneration destroys the light-sensitive tissue in the center of the retina, causing vision to fail gradually from the center outwards.
The new drug, Macugen, attacks the rapidly progressing “wet” type of AMD, in which new blood vessels form behind the retina and then leak, damaging the macula. That form affects an estimated 1.6 million Americans over 50, and some 6.3 million are expected to be affected by 2030 as the massive “baby boom” generation ages. Macugen inhibits the protein VEGF, slowing the growth of these blood vessels. VEGF has been shown to play a role in abnormal blood vessel growth.
“It’s the first pharmaceutical directed to the basic pathology of the disease,” said Dr. Donald J. D’Amico, a professor of ophthalmology at Harvard Medical School, who conducted clinical trials of the drug. D’Amico said that untreated patients had about a 45% chance of significant vision loss in a year compared to 30% for patients treated with Macugen.
Macugen, chemically known as pegaptanib sodium injection, is being jointly developed and marketed by Eyetech Pharmaceuticals and Pfizer Inc. It is expected to be available to doctors early next year. It is injected into the vitreous gel in the eye, D’Amico said. He said the injections were well tolerated by patients, with more than 90% continuing with the treatment. Other treatments for wet AMD include laser surgery to destroy the fragile, leaky blood vessels or a light-sensitive drug that is injected and then activated to destroy the blood vessels by shining a light in eye.
© 2004: Indian Express Newspapers (Bombay) Ltd.
End of article.
Any further reproduction or distribution of this article in a format other than a specialized format is an infringement of copyright.
Go to ...
Top of Page.
List of Categories.
Blind World Website
Designed and Maintained by:
All Rights Reserved.